About Careers MedBlog Contact us
Medindia LOGIN REGISTER
Advertisement

European Medical Agency Confirms Suspension of Drugs Over Flawed Clinical Trials

by Julia Samuel on May 23, 2015 at 3:58 PM
Font : A-A+

European Medical Agency Confirms Suspension of Drugs Over Flawed Clinical Trials

The European Medicines Agency recommended to suspend medicines which were based on clinical studies conducted at GVK Biosciences in Hyderabad and recently confirmed it.

"This is the outcome of a re-examination requested by marketing authorisation holders for seven of the medicines concerned," a statement from the Agency said.

Advertisement

As it has taken up the matter with the agency and a few other health regulators in Europe, this could be a further setback for the firm as well as the Government of India.

During the re-examination, the Agency's Committee for Medicinal Products for Human Use (CHMP) concluded that "concerns about reliability of the clinical studies remain... maintained its recommendation of January 2015 to suspend medicines for which no supporting data from other studies were available. This is with the exception of one medicine included in the re-examination for which concerns about studies were addressed."
Advertisement

In January 2015, French medicines agency (ANSM) inspected the company's facility that raised concerns about how GVK conducted studies at the site on behalf of marketing authorisation holders. "The inspection revealed data manipulations of ECGs during the conduct of some studies of generic medicines..."

The CHMP, however, noted that there is no evidence of harm or lack of effectiveness linked to the conduct of studies by GVK Biosciences at Hyderabad. The CHMP's recommendation will be sent to the European Commission for a legally binding decision.

The Agency said that this decision will apply to all member states irrespective of whether or not they have taken interim measures to suspend medicines.

Pharmaceuticals Export Promotion Council of India Director General P.V. Appaji had recently said the Centre felt that "it is not scientifically proved and the Commerce Ministry, Pharmexcil took up the issue. A delegation under Joint Secretary to the Commerce Ministry had met health regulators, including EMA authorities. The government has made it clear because it has major stake in our exports we will not take it lightly," he had said.

Source: Medindia
Advertisement

Advertisement
Advertisement

Recommended Reading

Latest Drug News

 Parkinson's Unmet Needs Creates Path for New Entrants into the Market
Addressing the unmet needs of Parkinson's Disease by providing disease-modifying therapies could bring about a major shift in the way that patients are treated.
How Microrobots Could Help Treat Bladder Diseases?
Microrobots could swirl through a person's blood stream, search for targeted areas to treat for various ailments.
How Can Multivitamin Supplements Slow Cognitive Aging?
Supplementation with multivitamins is an inexpensive way for older adults to slow down memory loss.
 Ivosidenib Approved for Acute Myeloid Leukemia & Advanced Cholangiocarcinoma
Some people with an aggressive blood cancer called acute myeloid leukemia (AML) may soon have a new drug option called Ivosidenib that blocks the activity of IDH1 gene.
Sacubitril/valsartan Unleashes Hope for Heart Failure Patients
In case of cardiac failure where the ejection fraction is greater than 40%, sacubitril/valsartan can prove to be quite beneficial
View All
This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close
×

European Medical Agency Confirms Suspension of Drugs Over Flawed Clinical Trials Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests